Please assess the completion status of the following clinical trial:

Trial Title: Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age~* ER Negative and PR Negative~* Progression of disease in the metastatic setting despite taxane or other chemotherapeutic therapies including Herceptin (patients on Herceptin may continue this therapy while on study)~* Maximized chemotherapy in the metastatic setting or patient experienced side effects contributing to decreased quality of life and elects to defer chemotherapy~* Evaluable disease by either:~  * CT Scan with or without contrast (lesions must be greater than 2 mm)~ * PET Scan, or Bone Scan, or Plain skeletal films~ * Chest wall or skin recurrence (digital photo to capture evaluable disease)~* Evaluable symptoms (pain, shortness of breath, fatigue, anorexia)~* Performance Status of 0, 1, or 2~* Bilateral mammogram performed within one year before registration~Exclusion Criteria:~* Uncontrolled hypercalcemia greater than 11~* Uncontrolled congestive heart failure greater than 2 NYHA class~* Central Nervous System metastasis~* Concomitant steroid use~* Performance Status of greater than 2~* Bilirubin greater than 5.5

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).